- Cispoly, a China-based developer of women’s health screening tools, has raised $14 million in a Series B round led by Saudi Aramco’s investment arm Prosperity7 Ventures.
- Cispoly’s lead product Ciscer uses methylation analysis to screen for cervical cancer. The startup is also developing tests for endometrial and ovarian cancers.
- The fresh funding will support Cispoly’s R&D efforts and global expansion plans, starting with Southeast Asia and Europe.
Cispoly, a China-based developer of women’s health screening tools, has raised a fresh round of funding led by Saudi Arabian oil giant Aramco’s investment arm Prosperity7 Ventures.
The Beijing-based startup secured over $14 million in its Series B financing round. Existing backer Sunland Fund also participated. This brings Cispoly’s total funding to date to around $20 million.
Founded in 2020 by Liu Pei, Cispoly is focused on early detection of gynaecological cancers. Its lead product Ciscer screens for cervical cancer using methylation biomarker analysis. Ciscer received approval from Chinese regulators in March.
Also Read: Saudi Vision 2030: Analyzing the Pillars and Mega ProjectsThe startup is now working to expand its product line. Its pipeline includes Cisendo for endometrial cancer detection and Cisova for ovarian cancer screening. Both are currently undergoing clinical studies.
Cispoly plans to use the new capital to accelerate research efforts and expand globally. It recently kicked off partnerships with medical institutions in China and looks to enter Southeast Asia and Europe soon.
Prosperity7 Ventures seems keen on Chinese healthcare startups. It previously invested in two funding rounds for exoskeleton robot maker Fourier Intelligence. The Aramco fund also backed mental health firm Jiandanxinli and AI drug discovery startup Insilico Medicine.
With rising interest in women’s health technology, Cispoly looks well-placed to capitalize on the growing demand for its innovative screening tools. The latest funding round validates its technology and will aid its mission to make gynaecological cancer detection accurate, affordable and accessible.
Follow us on Instagram, LinkedIn, and Twitter for startup & business news and inspiring stories of MENA businesses, entrepreneurs, startups, innovators, investors, and change-makers.
To report any issue or error in the story, please email us editor [at] rasmal [dot] com.
Last Updated on December 28, 2023 by Safiya K
